ABSTRACT: The derivation of gametes from patient-specific pluripotent stem cells may provide new perspectives for genetic parenthood for patients currently facing sterility. We use current data to assess the gamete differentiation potential of patient-specific pluripotent stem cells and to determine which reprogramming strategy holds the greatest promise for future clinical applications. First, we compare the two best established somatic cell reprogramming strategies: the production of induced pluripotent stem cells (iPSC) and somatic cell nuclear transfer followed by embryonic stem cell derivation (SCNT-ESC). Recent reports have indicated that these stem cells, though displaying a similar pluripotency potential, show important differences at the epigenomic level, which may have repercussions on their applicability. By comparing data on the genetic and epigenetic stability of these cell types during derivation and in-vitro culture, we assess the reprogramming efficiency of both technologies and possible effects on the subsequent differentiation potential of these cells. Moreover, we discuss possible implications of mitochondrial heteroplasmy. We also address the ethical aspects of both cell types, as well as the safety considerations associated with clinical applications using these cells, e.g. the known genomic instability of human PSCs during long-term culture. Secondly, we discuss the role of the stem cell pluripotency state in germ cell differentiation. In mice, success in germ cell development from pluripotent stem cells could only be achieved when starting from a naive state of pluripotency. It remains to be investigated if the naive state is also crucial for germ cell differentiation in human cells and to what extent human naive pluripotency resembles the naive state in mouse.
Introduction
Human pluripotent stem cells (hPSC), both embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC), have opened new opportunities in regenerative medicine. One of the most heavily debated possible applications is the derivation of gametes, or in-vitro gametogenesis (IVG) from these stem cells, with several downstream application possibilities. First of all, it can shed light on the pathways involved in in-vivo gametogenesis, a process that is difficult to study in the human due to clear ethical constraints. This research model could help in finding new targets for the treatment of several forms of infertility, or could be utilized in toxicity testing. Secondly, the in-vitro derived gametes could be applied clinically, ultimately aiming at reproduction. Stem cell-derived gametes have been proposed as a new source of donor gametes and as a means of establishing genetic parenthood for those people who do not or no longer produce functional gametes (Segers et al., 2017) . Importantly, when aiming at the derivation of gametes, the use of patient-specific hPSC is a prerequisite. Two hPSC types could be envisaged as possible cell source: iPSC or hESC derived from somatic cell nuclear transfer (SCNT) embryos (SCNT-hESC). Although both cell types have been proven to be pluripotent, considerable differences have been reported at the molecular level. Since gametes ensure the creation of a new individual and are responsible for transmitting the (epi)genetic information across generations, aberrations in these cells will have tremendous implications. Furthermore, recent advances in stem cell research have shown that 'pluripotency' is not a defined state, but exists at different levels, mainly depending on the culture conditions of the stem cells. This pluripotent state, however, may in turn influence the efficiency of germ cell differentiation. In this review, we therefore aim to shed light on the possible implications in terms of germ cell differentiation efficiency and safety upon application of stem cell-derived gametes when considering the type of hPSC as starting material.
iPSC Versus SCNT-hESC
Induced pluripotent stem cells
The first human iPSC lines were created by Yamanaka by overexpression of SOX2, KLF4, POU5F1 and c-MYC in fibroblasts using retroviral vectors (Takahashi et al., 2007) . These ectopic expressed factors enforce a hyperdynamic chromatin state, subsequently causing a global change in gene expression and the conversion to pluripotency (Buganim et al., 2013) . The choice of reprogramming factors can have an important effect on the efficiency and safety of the reprogramming. Both KLF4 and c-MYC, for example, are known oncogenes and several alternative factors have been introduced. Yu et al. (2007) showed that KLF4 and c-MYC can be replaced by NANOG and LIN28, leading to a safer, yet less efficient reprogramming process. Another example is the histone-remodelling chaperone ASF1A, which, in combination with POU5F1, could reprogram fibroblasts to iPSC in the presence of the oocyte-specific growth factor GDF9 (Gonzalez-Munoz et al., 2014) . Modulation of epigenetic processes by exogenous compounds may facilitate cell fate conversion by making cells more permissive to epigenomic remodelling. Especially compounds that modulate epigenetic enzymes, such as histone deacetylase (HDAC), histone methyltransferase (HMT), histone demethylase (HDM) and DNA methyltransferase (DNMT), are of interest (Stadtfeld et al., 2010; Cao et al., 2012) . The choice of starting cell type may also affect the reprogramming efficiency and quality. The more globally permissive chromatin structure of adult stem cells and progenitor cells may facilitate the reprogramming efficiency and increase the quality of the obtained iPSC lines (Eminli et al., 2009; Kim et al., 2011; Cao et al., 2012) ; while cells with extensive proliferative capacity or those expressing certain transcriptional regulators (Aasen et al., 2008) may also display more efficient reprogramming than the widely used fibroblasts. The first methods developed for overexpression of reprogramming factors, relying on viral genomic integration, were efficient but are not applicable in the clinic due to the risk of insertional mutagenesis (Kustikova, 2005) or reactivation of the reprogramming factors (Nakagawa et al., 2008) . The more recent, both viral and non-viral, transient systems minimize the risk of genomic recombination or insertional mutagenesis, but still involve the introduction of foreign DNA into the cells. These include PiggyBac transposons (Woltjen et al., 2009) , zinc finger nucleases (Ramalingam et al., 2013) , minicircles (Jia et al., 2010) and episomal vectors Okita et al., 2011) . RNA-based iPSC induction methods are often considered for clinical use as they avoid all risk of genomic insertion. The transfection of mRNA encoding reprogramming factors is probably one of the safest techniques and has been shown to efficiently generate iPSC (Warren et al., 2010 (Warren et al., , 2012 Yakubov et al., 2010; Kehler et al., 2017) . The main drawback for the use of mRNA is the short expression window, resulting in the necessity for repeated transfections. Alternatively, the use of a self-replicative Venezuelan equine encephalitis (VEE) virus RNA replicon (Yoshioka et al., 2013) or a Sendai virus have been reported (Fusaki et al., 2009) . However, both the Sendai virus and the RNA replicons require activation of cellular innate immunity to be cleared from the cytoplasm. Finally, approaches have been developed to replace ectopic expression of reprogramming factors by proteins (Kim et al., 2009; Zhou et al., 2009) or small molecule cocktails (Hou et al., 2013) . These molecules target the same biological pathways, but do not require additional manipulation of the cells for delivery. However, they can display high cellular toxicity due to off target effects, even if they are highly specific to their target (Biswas and Jiang, 2016) .
Somatic cell nuclear transfer-derived hESC
Initially, generation of SCNT-ESCs proved to be more difficult in humans compared to other species. Following the first primate success in the rhesus macaque in 2007 (Byrne et al., 2007) , human SCNT-ESC derivation was finally achieved in 2013 (Tachibana et al., 2013) . Human foetal fibroblast nuclei were fused with the recipient oocyte by use of an inactivated Sendai virus and reconstructed cells were stimulated by an electric pulse in the presence of 6-DMAP (serine/threonine inhibitor) and histone deacetylase inhibitor trichostatin A (TSA). The addition of caffeine, a potent phosphatase inhibitor, prevented premature exit from metaphase II during fusion (Tachibana et al., 2013) . A major contributing factor of the above success was the use of in-vivo matured fresh oocytes from young donors, which proved to be more beneficial over the use of spare in-vitro matured oocytes, which frequently lead to embryonic developmental arrest (Heindryckx et al., 2007) . As a result, 6 out of 52 human SCNT embryos developed into blastocysts and were utilized for ESC isolation, giving rise to ESC-like colonies and stable diploid human ESC lines (Tachibana et al., 2013) . Several independent groups confirmed the derivation of human SCNT-ESC (Chung et al., 2014 (Chung et al., , 2015 Yamada et al., 2014) and also evaluated the effect of the donor cell age along with the time interval between fusion and activation in reprogramming success. Chung et al. used a modified approach to generate hESC from dermal fibroblasts (DFBs) from 35 and 75-year-old males, proving that nuclear donor age does not impede SCNT cloning success (Tachibana et al., 2013; Chung et al., 2014) . Yamada et al. (2014) further adjusted the protocol by diluting Hemagglutinating virus of Japan Envelope (HVJ-E) in Ca 2+ -free medium in an attempt to minimize premature exit from meiosis to even lower levels. Further optimization was achieved by the introduction of demethylases, aiming to aid reprogramming of reprogramming resistant regions (RRR) in the somatic cells (Chung et al., 2015; Deglincerti and Brivanlou, 2015) . These experiments significantly improved the efficiency of the process but also demonstrated that SCNT success is not confined to specific cell types and it is not related to the donor age (Cibelli, 2014; Wolf et al., 2017) .
Overall, the prospect of using human SCNT-hESC for clinical purposes will depend on factors determining the safety and efficacy of the procedure along with ethical and legislative restrictions. Furthermore, one of the major factors limiting the application of SCNT for the derivation of ESCs is the shortage of donor oocytes for research (see below).
Ethical considerations regarding the reprogramming method
Regardless of the technical advantages of one reprogramming method over another, the choice for a preferred strategy will ultimately also be influenced by ethical concerns.
First, current legislations in many countries/states prohibit (public funding of) the creation of SCNT-hESC, but not of iPSC, due to the contentious nature of the creation and destruction of human embryos for research purposes, an essential step in the creation of SCNThESC, but not of iPSC (Mertes, 2012; National Conference of State Legislators, 2017) . Bear in mind, however, that regardless of which source of pluripotent stem cells is used, if IVG is ever to be introduced in the clinic it will have to be preceded by extensive preclinical research. This will include functional assessment of the created gametes, which can only be done by creating embryos in the lab. Subsequently, these embryos will then need to be destroyed in order to investigate whether there are any (epi)genetic abnormalities present in the embryos that were created by the IVG process. In jurisdictions that do not allow embryo creation for research purposes, preclinical trials, even with iPSC, will therefore not be possible.
Second, the SCNT-hESC route also requires a source of human oocytes. While the short 'supply' of oocytes for research is an issue that IVG might be able to tackle in the future, at least in the short run, oocytes will need to be donated by healthy donors, which is a contentious issue in itself (Mertes and Pennings, 2007) . Also, it is arguably not an efficient use of a scarce resource such as oocytes to use them to make other (patient specific) oocytes, rather than using the donor oocytes directly in infertility treatment. A critical note to this last argument, however, is that not all donors who consent to the former would also consent to the latter. A third objection to using human oocytes in IVG research, at least for the production of the female gamete, is that the mtDNA of the donor would be present in the resulting oocytes, which has led some people to identifying the donor as a third genetic parent in the mitochondrial transfer debate (Ravitsky et al., 2015) .
Third, in the SCNT-hESC route, an embryo (which is a genetic clone of one of the prospective parents) is first created, to then be destroyed to harvest ESC in order to create a different embryo (which is genetically matched to both parents). This may be troublesome if the first embryo is perceived as an extra generation between the prospective parents and the eventual child, leading to assertions that the child would have an 'embryonic mother/father' that was killed in order for him/her to be created (Mertes and Pennings, 2008; Sparrow, 2012; Watt, 2014) .
Finally, whenever research relies on SCNT, or 'therapeutic cloning', there is a concern that improvements in the SCNT technique will eventually clear the way for reproductive cloning. Without elaborating on the reasons why, it suffices here to say that many people consider reproductive cloning to be unethical.
Despite these ethical concerns directed to the SCNT-hESC route, it would be wrong to draw the conclusion that we should only invest in the iPSC route. A very important factor in any ethical deliberation in reproductive medicine is safety and the wellbeing of the potential resulting children. If safety concerns in the iPSC route outweigh those in the SCNT-hESC route, the latter may end up being the preferable course of action. Also, in this early phase of research, it will be very informative to compare gametes formed through either route in order to enhance our understanding of gametogenesis and determine which route is most reliable and safe.
Effects and consequences of the reprogramming method

Genetic and epigenetic aberrations induced by the reprogramming method
Several groups have concluded that reprogrammed hPSC contain on average six to nine protein-coding mutations. This number is statistically indistinguishable between the two reprogramming methods, iPSC or SCNT-hESC (Gore et al., 2011a; Johannesson et al., 2014) . Whereas at least half of the observed mutations pre-existed in low frequencies in the donor cells the iPSC lines were derived from, the other mutations may be directly related to the reprogramming (Gore et al., 2011a; Ji et al., 2012; Young et al., 2012; Johannesson et al., 2014) . A further study confirmed that these protein-coding mutations are intrinsic to the reprogramming process and independent of the somatic donor cell type (Ruiz et al., 2013) . Whilst often these mutations were enriched in cancer-related genes, the observed point mutations do not seem to provide a selective functional advantage to the cells during reprogramming, and thus do not favour cell reprogramming (Gore et al., 2011a; Ruiz et al., 2013) . Copy number variations (CNVs) have been frequently reported in hiPSC. Surprisingly, Hussein et al. showed that a significantly higher proportion of early-passage iPSC carry CNVs when compared to intermediate-passage iPSC. The authors claimed that most of the de-novo CNVs, obtained during reprogramming, conferred a selective disadvantage to the cells, driving their loss from further culture (Hussein et al., 2011) . Using a more sensitive deep sequencing approach, Abyzov et al. (2012) showed that the CNVs reported in iPSC are the result of low-grade genetic mosaicism in the donor cells, rather than the result of de-novo generation during reprogramming. These results are in agreement with the finding of the Mitalipov lab, who compared CNVs and InDels in isogenic iPSC and SCNT-hESC and IVF-hESC and found no statistically significant differences between these three cell types (Ma et al., 2014) .
While most groups seem to agree that at the genetic level there is no significant difference between SCNT-hESC and hiPSC, the epigenetic status of these cells remains more controversial. Epigenetic alterations in reprogrammed hPSC can be divided into two groups. If the modification stems from the donor cells, it can be regarded as a residual epigenetic memory; otherwise an aberrant modification can be acquired during and due to the reprogramming process itself. Several groups have reported an epigenetic memory in hiPSC, often linked to a marked difference in differentiation potential (Bar-Nur et al., 2011; Kim et al., 2011; Ohi et al., 2011) . However, recent studies have shown that the parental cell type contributes only minimally to hiPSC variability, whereas most of the epigenetic variation, and thus differentiation potential, in hiPSC can be explained by inter-individual genetic variation Kajiwara et al., 2012; Mills et al., 2013; Nasu et al., 2013; Rouhani et al., 2014; Nishizawa et al., 2016; Carcamo-Orive et al., 2017; Kilpinen et al., 2017) .
A frequent loss of imprinting (LOI) has been reported in hiPSC and SCNT-hESC, while in conventionally derived hESC genomic, imprinting seems to be more stable Nazor et al., 2012; Johannesson et al., 2014; Ma et al., 2014; Bar et al., 2017) . While Ma et al. (2014) reported a higher incidence of LOI in hiPSC when compared to SCNT-hESC, this could not be confirmed by Johannesson et al. (2014) , who found similar variation in imprinted differentially methylated regions (iDMRs) in SCNT-hESC and hiPSC, mostly due to hypomethylation. However, most studies were performed on a limited number of lines or they investigated a limited number of imprinted genes. Moreover, different derivation and analysis techniques were applied, which may have influenced the outcome. Recently, Bar et al. applied a large-scale analysis of allele-specific mRNA sequencing data of 270 hPSC samples obtained from different labs, allowing them to investigate all known imprinted genes in a large cohort of hPSC lines. Their study confirmed that reprogrammed cells, both iPSC and SCNT-hESC, show an~2-fold increase in LOI when compared to IVFhESC, already at low passages. They did not detect a difference between these two reprogrammed cell types. Moreover, they found that imprinted genes controlled paternally are more prone to aberrations than maternally controlled genes and that some of the aberrations originate already from the somatic origin of the cells (Bar et al., 2017) .
Early papers looking into DNA methylation in genomic regions other than imprinted ones demonstrated fundamental differences in iPSC when compared to IVF-hESC. These studies demonstrated the occurrence of iPSC-specific aberrantly methylated (both hypo-and hypermethylated) loci, prevalent in both CG and non-CG context (Deng et al., 2009; Doi et al., 2009; Hu et al., 2010; Kim et al., 2010; Lister et al., 2011) . Moreover, Lister et al. reported that iPSC display numerous non-randomly distributed megabase-scale regions that are aberrantly methylated in the non-CG context. These regions could be spatially linked to a regional enrichment of particular covalent histone modifications (such as H3K9me3), which may impart a regional chromatin conformation that is resistant to complete reprogramming. Importantly, these differentially methylated regions are transmitted to differentiated cells at a high frequency (Lister et al., 2011) . A later study, however, concluded that the variation in DNA methylation observed between iPSC and IVF-hESC is actually similar to the interhESC variation (Bock et al., 2011) . Also, as it was shown that adherent in-vitro culture can lead to large-scale regional H3K9me3-enrichment (Zhu et al., 2013) , therefore culture stress could at least partly be the cause of the large-scale hypomethylated regions. At this moment, the epigenetic integrity of iPSC remains controversial. While several groups report comparable errors in iPSC and hESC (Bock et al., 2011; Mallon et al., 2014; Choi et al., 2015) , others have found iPSC-specific aberrant methylation hotspots (Lister et al., 2011; Nishino et al., 2011; Ruiz et al., 2012; Salomonis et al., 2016) . Since the reprogramming factors and method could also have an important influence on the epigenetic landscape of iPSC lines, whole genome single base sequencing of a plethora of lines will be needed to reveal the true identity of differential methylation. Only the Mitalipov group has performed whole genome bisulphite sequencing on SCNT-hESC. They reported that SCNThESC cluster more closely to IVF-hESC when compared to iPSC, mainly due to a residual epigenetic signature of the donor somatic cells. However, more lines will need to be examined in order to be able to make adequate conclusions on the differences between these cell types.
Mitochondria
IPSC derived from somatic cells of older patients can carry high loads of mitochondrial DNA (mtDNA) variants, affecting the functionality of differentiated cells (Kang et al., 2016) . One of the defining features of SCNT-hESC is that the mtDNA originates almost exclusively from metaphase II oocytes from healthy donors, exhibiting a lower mutation rate and eventually fewer mutations (Trounson and Dewitt, 2013) . Importantly, the quality of the oocytes and their mtDNA may depend on the age of the donor and the ovarian stimulation protocol used for oocyte retrieval. Tachibana et al. (2013) hypothesized that young donors who produced <12 oocytes per cycle present the best candidates for SCNT.
Only a small amount of somatic cell mtDNA is transferred to the resultant embryo during SCNT leading to heteroplasmy, but studies have shown that mtDNA carryover is <5% and can become undetectable during further culture (Tachibana et al., 2013; Ma et al., 2015) . This attribute of SCNT-hESC represents an advantage over iPSC as high quality mtDNA provides the potential to support metabolically superior cells destined for ES cell therapies, regardless of the nuclear donor cell mtDNA (Tachibana et al., 2013) .
Consequences on the applicability and safety of the differentiated progeny
Whether or not SCNT-hESC and iPSC differ significantly at the epigenetic level remains to be elucidated. It is important to bear in mind that epigenetic aberrations may lead to developmental defects. A wellknown example was reported by Nayernia and colleagues who differentiated mESC into haploid male gametes. Live pups were born after intracytoplasmic injection of the obtained gametes into oocytes and embryo transfer to a pseudo-pregnant mouse, but all were either smaller or larger than controls and died prematurely, probably due to disturbed establishment of male germline-specific methylation imprints (Nayernia et al., 2006) . Whereas genetic defects are imprinted in the cells and undoubtedly inherited by descendent cells, some epigenetic aberrations could, in theory, be corrected during the actual IVG or even after fertilization, as in both events profound epigenetic remodelling takes place (Fraser and Lin, 2016) However, it is to date unclear whether this later remodelling could be sufficient to correct possible reprogramming-induced epigenetic aberrations.
Though there seems to be no difference in the levels of genetic aberrations, both SCNT-hESC and iPSC contain a significant number of small or large mutations. As it may not be possible to exclude any de-novo change in an hPSC line, the identification of possibly harmful mutations may be crucial, but also very difficult. Genes that are clear candidates for exclusion of a line if mutated are, e.g. those implicated in (early) lineage differentiation pathways (Ortmann and Vallier, 2017) , since improper expression could lead to developmental defects. But also mutations affecting genes that impact later differentiation or maturation could impair development. Genetic aberrations could also be harmful later in life. For example, mutated or mis-regulated oncogenes, often reported in hPSC lines Merkle et al., 2017) , could make an individual born from the use of in-vitro derived gametes more susceptible to develop cancers during childhood or adulthood. The difficulty in predicting possible effects on the short-or long-term creates an important hurdle for a future clinical application of stem cell-derived gametes.
In terms of germ cell differentiation potential, no comparisons between different pluripotent stem cell types have been made in the human. Hikabe and colleagues showed that, in the mouse, both conventional ESC and iPSC can generate gametes in vitro, but did not quantify efficiency, nor include NT-ESC (Hikabe et al., 2016) .
Safety concerns associated with clinical applications
Aging of somatic cells, donor cells for both iPSC and SCNT-hESC, is generally characterized by increased DNA damage and genomic instability (Lombard et al., 2005; Garinis et al., 2008) . It has been shown that iPSC generated from elderly subjects contain increased numbers of genetic abnormalities such as higher numbers of point mutations, large genomic rearrangements and exome mutations when compared to hESC (Mayshar et al., 2010; Laurent et al., 2011; Abyzov et al., 2012; Johannesson et al., 2014) . The rate of mtDNA point mutations and large deletions is also higher, however, mutations in proliferating peripheral tissues such as skin and blood that are most commonly used for iPSC reprogramming are usually low and limited to non-coding variants (Schon et al., 2012; Yao et al., 2015) .
Apart from aberrations acquired before or during reprogramming, there is an increasing body of evidence that hPSC are prone to (epi) genetic instability during in-vitro culture (Lund et al., 2012; Nguyen et al., 2013) . Several highly recurrent chromosomal abnormalities have been reported in hPSC lines worldwide (Spits et al., 2008; Amps et al., 2011) , which take over the culture due to a selective advantage conferred to the cells . Moreover, it has been shown that hPSC lines display low-grade mosaicism of genetic abnormalities . As a certain abnormality may only be present in a few cells, analysing the bulk genetic content of an hPSC line may not give the correct information at the single cell level. New methods based on massive parallel sequencing could give information up to the single nucleotide level and with higher sensitivity. Also at the epigenetic level, an accumulation of heterogeneity has been observed in CpG methylation (Tanasijevic et al., 2009; Nazor et al., 2012) as in X chromosome inactivation patterns (Geens and Chuva De Sousa Lopes, 2017) . Importantly, these culture-induced (epi)genetic alterations often have phenotypic consequences (Bock et al., 2011) . In general, the longer an hPSC line is in culture, the higher the chance that it will have acquired one or more (epi)genetic aberrations. Therefore, shorter culture periods should best be applied when considering clinical applications. However, still-suboptimal culture conditions are often identified as a possible cause of the high level of (epi)genomic instability in hPSC (Garitaonandia et al., 2015; Jacobs et al., 2016; Geens and Chuva De Sousa Lopes, 2017) . Therefore, modifications to the culture process may help in avoiding or at least reducing the number of culture-acquired aberrations.
Naïve versus primed pluripotency
Mouse pluripotent stem cells
Embryonic development progresses from a state of 'totipotency' in the zygote towards cells which are more restricted in their differentiation potential (Nichols and Smith, 2012; de Paepe et al., 2014) . In mice, the first embryonic stem cells (mESC) were isolated from the pre-implantation inner cell mass (ICM) in 1981 (Evans and Kaufman, 1981) . These mESC shared some characteristics with the ICM cells and could potentially develop into the three germinal layers when injected into mouse blastocysts, a hallmark of pluripotency. This was supported by the key expression of POU5F1, SOX2 and NANOG and was later termed as 'ICM-like' or 'naïve' pluripotency. In addition, these naïve stem cells displayed compact dome-shaped colonies, and were characterized by their dependency on JAK-STAT signalling, active X chromosomes (XaXa) in cell lines derived from female embryos and absence or very low expression of Major Histocompatibility Complex-I (MHC-I) (Warrier et al., 2017) .
During continued in-vivo embryo development, the second lineage segregation occurs with the differentiation of the ICM into the epiblast and the hypoblast, which form the embryo and the yolk sac, respectively. Specifically, upon implantation in rodents, epithelialisation of the epiblast is triggered to form an egg cylinder, while in other mammals the epiblast develops as a flat disc, a difference believed to be an important regulatory mechanism marking deviation from 'naïve' pluripotency ). The clonal analysis of cells from the post-implantation epiblast revealed that they can form all three germ layers (Lawson et al., 1991; Nichols and Smith, 2012) , but failed to integrate and form chimeras when injected into mice blastocysts (Tesar et al., 2007; Guo et al., 2009) . In 2007, independent pluripotent mouse stem cell lines were derived from the post-implantation epiblast for the first time, in media supplemented with FGF2 and Activin A (Brons et al., 2007; Tesar et al., 2007) . These stem cells, termed mouse epiblast stem cells (mEpiSC), showed restricted in-vitro differentiation potential compared to naïve mESC, formed flat colonies, grew poorly as single cell clones, depended on TGF/Activin/Nodal signalling, displayed one inactivated X chromosome in female lines, tested positive for MHC-I antigen expression, heterogeneously expressed lineage commitment markers and showed a poor chimera contribution upon injection into post-implantation blastocysts (Hanna et al., 2010b; Fujishiro et al., 2013) . Therefore, these mEpiSC were said to display a more 'primed' pluripotent profile.
As such, it became clear that in pluripotent cells isolated from different mammalian species, there exist at least two states of pluripotency, the naïve and the primed state (Hanna et al., 2010b) , with the latter exhibiting some predisposition for differentiation towards certain lineages.
Different states of pluripotency in human cells
Pluripotency is a transient state in vivo, however, distinct states of pluripotent stem cells have been established in vitro, depending on the developmental embryonic stage they were derived from, as well as the culture conditions used for derivation or expansion (Weinberger et al., 2016) . These different states of pluripotency can be interconverted through the modulation of both intrinsic cellular and exogenous factors (Hanna et al., 2010b) . To fully realize the potential of pluripotent stem cells, particularly in terms of their functional differentiation capacity, it is imperative to have a good understanding of their molecular and epigenetic determinants and the pathways directing different states of pluripotency.
The first successful derivation of hESC from the pre-implantation ICM was reported in 1998 (Thomson, 1998) . These hESC deviated from their murine counterparts in their transcriptional and epigenetic profile, morphology and culture requirements, exhibiting a state of 'primed pluripotency' ) with some properties more analogous to those of mouse epiblast stem cells. This suggests that the human inner cell mass progresses in vitro through an epiblastlike state before hESC emerge in culture ( Van der Jeught et al., 2015) , an hypothesis that is supported by the identification of the post-ICM intermediate (PICMI), a transient epiblast-like structure displaying a unique transcriptional profile of a mix of early and late epiblast markers (O'Leary et al., 2012) .
The primed characteristics of conventionally derived hESC include a lack of global hypomethylation as seen in ICM cells, a lack of pre-Xinactivation as seen in some female murine naïve cell lines, lower expression of naïve markers such as KLF17 and DPPA3, deposition of H3K27em3 over developmental genes and a lack of nuclear localization of transcription factor E3 (TFE3) (Weinberger et al., 2016) . However, higher expression of some naïve markers such as PRDM14, NANOG and E-CADHERIN and the absence of FGF5 and N-CADHERIN upregulation suggests that hESC are relatively less 'primed' than mEpiSC (Weinberger et al., 2016) .
Switching between pluripotent states
Accumulating evidence has shown that primed hPSC can be reverted back to the naïve pluripotent state and vice versa by a variety of genetic manipulations and/or culture conditions (Hanna et al., 2010b) . Transitioning towards the naïve state would allow increased homogeneous stem cell cultures for efficient directed differentiation as well as help avoid the drawbacks associated with primed cultures.
The earliest attempts to reprogram hPSC to a naïve-like state depended on transgenes expressing OCT4, KLF4, KLF2 and NANOG in various combinations and levels of expression (Hanna et al., 2010a; Theunissen et al., 2014) . However, this process was considered cumbersome and transgene-free conditions were investigated to generate alternative routes to naïve pluripotency. In permissive mice strains, exposure to LIF/STAT3 signalling combined with culture in '2i' conditions (PD0325901 and CHIR99021) or exogenous expression of naïve stem cell markers boosted conversion of mEpiSC to naïve mESC-like cells (Ying et al., 2008; Hanna et al., 2010a) ; yet this strategy failed in hESC (Davidson et al., 2015; Van der Jeught et al., 2015) . However, further adaptations to the combinations of small molecules added to the culture medium resulted in the successful modulation of signalling pathways governing the naïve pluripotency (Table I) . Naïve hESC were also directly derived from the ICM of human pre-implantation embryos, however with low or unreported efficiency (Gafni et al., 2013; Theunissen et al., 2014; Ware et al., 2014) . Guo et al. derived naïve hESC with higher efficiency (4 lines out of 14 ICM) by plating ICMs in serum-free media complemented with GSK3 and MAPK/Erk pathway and PKC signalling inhibitors, but detected chromosomal aberrations in three of the four derived lines .
The successful derivation of naïve-like pluripotency from primed cells and vice versa, using a variety of small molecules and/or transgenes, has led to the conclusion that the identity of the pluripotent state is defined by the derivation and growth conditions of the stem cells and not by their origin (i.e. ICM, pre-or post-implantation epiblast) (Hanna et al., 2010b) . Only recently, state-specific molecular markers have been identified to distinguish between pluripotency states in hPSC (Collier et al., 2017) .
Impact of the pluripotency state on germ cell differentiation potential
In vivo, the mammalian germline originates in the post-implantation epiblast from a cluster of cells of somatic origin in response to extrinsic signals and gives rise to primordial germ cells (PGC), the diploid precursors of germ cells. In vitro, it is possible to direct mPSC to form germ cells in the presence of an optimal set of extrinsic signals in culture, but only when naïve mESC were first modified to epiblast-like cells as a starting population (Hayashi and Saitou, 2014) . No success could be achieved in IVG when starting from EpiSC. Assuming that germline specification in vivo takes place during the transition of the ICM to the epiblast (Irie et al., 2015) , it is likely that hPSC will acquire germline competence during the transition from the naïve to the primed pluripotent state in the in-vitro recapitulation of the process.
Epiblast-like cells as progenitors
While it was postulated that in mice, mEpiSC should possess germline competence as they retain properties of the in-vivo epiblast, differentiation attempts resulted in negative or extremely low (1.5%) germ cell induction (Hayashi et al., 2011) . Germline competence in mEpiSC may be compromised as a result of their heterogeneous profile, based on their developmental origin in either early or late epiblast as seen in the study by Han et al., 2010 which observed a minor fraction of OCT4 positive EpiSCs as indicators of the early epiblast which could readily contribute to chimeras while the rest could not (Han et al., 2010) . To obtain a better germ cell precursor state, a culture system was devised to convert naïve mPSC to an epiblast-like state (EpiLC), reporting a successful derivation of PGC-like cells (PGCLC) (Hayashi et al., 2011; Zhou et al., 2016) . These mEpiLC had a cellular state similar to pregastrulating epiblasts, but distinct from EpiSC (Table II) (Hayashi et al., 2011) . Based on gene expression and epigenetic status, the mode of differentiation of naïve mPSC is very similar to that of ICM to epiblast in vivo, asserting successful germline differentiation from a naïve pluripotent state (Hayashi and Saitou, 2014) . Male germline induction with BMP4, SCF, EGF and LIF followed by transplantation into the seminiferous tubules of mice lacking germ cells or co-culture with Sertoli cells generated gametes leading to healthy progeny (Hayashi et al., 2011; Zhou et al., 2016) . The same group also recapitulated the process of oogenesis in mice from an EpiLC state by transplanting PGCLC into ovaries or by co-culturing the PGCLC with foetal gonadal cells, and obtaining fertile progeny, although with limited efficiency (Hikabe et al., 2016) .
PGCLC induction in humans
Initial attempts to derive germline descendants from human PSCs included spontaneous differentiation of primed hESC lines as monolayers (Eguizabal et al., 2011) or embryoid bodies with or without the presence of recombinant human BMP4, BMP8b and BMP7 molecules, which had been previously identified in the mouse model (Clark et al., 2004; Kee et al., 2009; Gkountela et al., 2013) . The yield of these studies was low and restricted by a lack of understanding of the key regulators of human PGC. Irie et al. (2015) developed a NANOS3-mCherry knock-in reporter hESC line for PGCLC induction and reported that in humans, the EpiLC condition did not confer germline competence, while primed hESC responded at very low efficiency (0-5%). However, hPSC cultured in '4i', a modified Naïve Human Stem cell Medium (NHSM) (Gafni et al., 2013) (Table 1) supplemented with FGF2 and TGFβ, responded to form PGCLC expressing Nanos3-mCherry and TNAP/ CD38 at very high yields (31-45%) after 4-5 days induction in media adapted to the human model from Hayashi et al. Most importantly, this study identified SOX17 as a key intrinsic regulator of germ cell fate and CD38 as an important germline specific cell surface marker in humans, in contrast to mice. Global gene expression analysis revealed transcriptome similarities between conventional primed hESC and those cultured in '4i' with similar expression levels of pluripotency factors (Blakeley et al., 2015; Pastor et al., 2016) . However, '4i' hESC showed a propensity towards mesodermal gastrulation states with, for example, the upregulation of T, RUNX1 and PDGFRA (Hayashi and Saitou, 2014; Irie et al., 2015) . More recently, Mitsunaga and colleagues defined '4i' as an ERK1/2 independent naïve cell line with weak expression of naïve markers such as KLF4 and TFPC2L1, similar to the primed condition. They showed that a 72 h culture of 'primed' hiPSCs in '4i' is sufficient to robustly induce hPGCLCs which resemble early stage PGCs randomly migrating in human embryo midlines before directional chemotaxis towards genital ridges (Mitsunaga et al., 2017) . Taking into account that a mesodermal commitment of the starter hPSC population might influence PGCLC induction, primed hPSC were pre-cultured for 2 days in presence of Activin A, BMP4 and FGF2 to obtain a mesoderm-like cell state (Sugawa et al., 2015) . Further culture in high concentrations of BMP4 supported by LIF/ROCKi for 4 days yielded TRA-1-81+/cKIT+ PGCLCs.
PGCLC induction was attempted using a hiPSC line bearing double promotors of PRDM1 and TFA2C in a pre-formulated commercial medium (Sasaki et al., 2015) in the presence of a WNT antagonist CHIR99021 to yield what the authors termed as incipient mesodermlike cells (iMeLC) with flat epithelial-like morphology and clear cell-tocell boundaries. Both the hiPSC and hiMeLC expressed 'naïve' markers similar to mEpiLC, but hiMeLC expressing markers of mesodermal lineage were at an intermediate developmental stage between that of pre-gastrulating mEpiLC and anterior primitive streak-like mEpiSC. hiMeLC yielded PGCLC expressing EpCAM and Intergin-α6 upon germline induction, but retained this competence only transiently. Global transcriptional and epigenetic analysis of these PGCLC showed a similar expression profile to those obtained by Irie et al., but major differences were observed when compared to the PGCLC profiles from Sugawa et 
NANOG KLF2
• First conversion of primed hESC towards naive, using hLIF (20 mg/l), MEKi (PD0325901 1 mM), GSK3i (CHIR99021 3 mM), and ectopic gene expression of OCT4 and KLF2/4. The PKA (protein kinase A) agonist forskolin (10 mM) can substitute for the ectopic transgene expression (*).
• Naive human stem cell medium (NHSM): hLIF (20 ng/ml), TFGb (1 ng/ml), bFGF (8 ng/ml), MEKi (PD0325901 1 mM), GSK3i (CHIR99021 3 mM), JNKi (SP600125 10 mM), p38i (SB203580 10 mM). Optimizing components (*) are PKCi (Gö6983 5 mM) and ROCKi (Y27632 5 mM).
• Reverse toggle protocol: pre-treatment with HDACi (0.1 mM sodium butyrate and 50 nM SAHA), culture with bFGF (10 ng/ml), MEKi (PD0325901 1 mM), GSK3i (CHIR99021 3 mM); for direct derivation: bFGF (10 ng/ml), MEKi (PD0325901 1 mM), GSK3i (CHIR99021 3 mM).
• 5i/LA medium: ectopic gene expression of NANOG and KLF2, followed by pre-treatment of cells with ROCKi (Y27632 10 mM) and by trysinization and culture in 5i/LA, MEKi (PD0325901 1 mM), GSK3i (CHIR99021 0.3-3 mM), BRAFi (SB590885 0.5 mM), SRCi (5WH-4-023 1 mM), ROCKi (Y27632 10 mM), hLIF (20 mg/l) and ActA (20 ng/ml).
• Two-step protocol including pre-treatment of cells with ROCKi (Y27632), followed by (1) ectopic gene expression NANOG and KLF2 and culture in 2iL/t2iL: hLIF (made in house), MEKi (PD0325901 1 mM), GSK3i (CHIR99021 3 mM in 2iL or 1 mM in t2iL); (2) t2iL+Gö: t2iL with PKCi (Gö6983 5 mM).
• Induction of naive pluripotency in hESC, using MEKi (PD0325901 1 mM), GSK3i (CHIR99021 3 mM), ascorbic acid (50 ng/ml), PKA agonist (forskolin 10 mM), bFGF (12 ng/ml) and hLIF (1000 U/ml). Abbreviations: MEKi, MAPK/Erk kinase inhibitor; GSK3i, Glycogen synthase kinase 3 inhibitor; JNKi, Jun N-terminal kinase inhibitor; p38i, p38 mitogen-activated kinase inhibitor; PKCi, Protein kinase C inhibitor; ROCKi, Rho-associated coiled-coil kinase inhibitor; TGFβi, Transforming growth factor β inhibitor; BRAFi, B-Raf inhibitor; SRCi, Src (sarcoma) inhibitor; PKA, Protein kinase A; bFGF, basic fibroblast growth factor; ActA, Activin A; hLIF, human leukaemia inhibitory factor; OCT4, Octamer-binding transcription factor 4; KLF2/4, Krüppel-like factor 2/4; NANOG, Nanog homeobox.
as an attempt to recapitulate in-vivo specification of hPGCs. For example, Duggal et al. (2013 Duggal et al. ( , 2015 reported on the role of Activin A in PGCLC formation. Von suggested that starting from already germline-competent hPSC, some epigenetic key steps in the priming phase were missed. Therefore, they decided to pre-induce naïve hPSC towards an EpiLC-state, but this resulted in a low yield of hPGCLC. Comparison of DNA methylation landscapes in hPGCs and hPGCLCs in vivo and in vitro demonstrated few differences in their epigenetic landscapes, while these were not observed in mice .
Discussion and Conclusions
Stem cell-derived gametes are the ultimate proof against the 'Weismann's barrier', which postulates that hereditary information moves only from germline to soma and never in reverse (Surani, 2016) . After the birth of healthy pups from stem cell-derived oocytes in mice (Hayashi et al., 2017) , also gamete derivation from hPSC in the human is making major leaps towards further applications. Despite the recent advancements in germ cell derivation from hPSC, this research has been hampered by a limited understanding of human germline induction in vivo. However, recently, RNA sequencing studies have identified genes essential for human germline development, distinguishing stage-specific molecular and epigenetic markers (Eguizabal et al., 2016; Li et al., 2017) . From the studies summarized above, it seems plausible that a pluripotent stem cell state with mesodermal commitment will be the most effective starting point for in-vitro germline induction. This suggests that in vivo, human PGC may originate at the onset of gastrulation from mesodermal precursors, and not from the pre-gastrulation epiblast, as in mice (Irie et al., 2015) . Further studies are warranted to see if the derived PGCLC can actually be matured into functional gametes, and whether co-culture with somatic cells within or without 3D scaffolds or organoids (Laronda et al., 2017) is needed for doing so (Eguizabal et al., 2011; Hayashi et al., 2011; Hayashi and Saitou, 2014) . Eventually, these gametes will need to fulfil robust functional and safety assays. However, it is important to note that these conclusions are extrapolated from the mouse model, and it may not be possible to form the same stringent evidence in human.
The question of which reprogramming method should be used when aiming for gamete derivation remains open. While iPSC conversion seems very attractive based on feasibility and ethical concerns, the epigenetic integrity of the obtained iPSC remains controversial. Moreover, both iPSC and SCNT-hESC show inherited and acquired genetic aberrations, ranging from the single nucleotide level to large chromosomal abnormalities. Also, low-grade mosaicism in hPSC lines will make it difficult to correlate bulk cell analysis to the single cell level that is required in gametes. One cannot analyse the (epi)genetic profile of a single stem cell-derived gamete if it is intended to be further used. The only option to obtain a correct molecular profile will be to analyse cells from an embryo obtained after fertilization using the stem cellderived gamete.
Together, this review highlights some major hurdles still to be overcome when considering gamete derivation from hPSC. Improvements both at the level of differentiation efficiency, and certainly in terms of safety, will be necessary before this technique may ever find its way to the clinic. 
Naïve mESC cultured for 2 days in the presence of Activin A and FGF2, yielded EpiLCs which expressed OCT4 strongly, while genes defining ICM origin such as SOX2, NANOG and PRDM14 were downregulated. Endodermal markers such as GATA4, GATA6 and SOX17 and BLIMP1, seen in PGC and EpiSC, were downregulated in EpiLC.
